Cargando…

Development of vaccines for SARS-CoV-2

COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a fe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Wern Hann, Liu, Xiang, Mahalingam, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431966/
https://www.ncbi.nlm.nih.gov/pubmed/32850116
http://dx.doi.org/10.12688/f1000research.25998.1
_version_ 1783571691454070784
author Ng, Wern Hann
Liu, Xiang
Mahalingam, Suresh
author_facet Ng, Wern Hann
Liu, Xiang
Mahalingam, Suresh
author_sort Ng, Wern Hann
collection PubMed
description COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.
format Online
Article
Text
id pubmed-7431966
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-74319662020-08-25 Development of vaccines for SARS-CoV-2 Ng, Wern Hann Liu, Xiang Mahalingam, Suresh F1000Res Review COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches. F1000 Research Limited 2020-08-17 /pmc/articles/PMC7431966/ /pubmed/32850116 http://dx.doi.org/10.12688/f1000research.25998.1 Text en Copyright: © 2020 Ng WH et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Ng, Wern Hann
Liu, Xiang
Mahalingam, Suresh
Development of vaccines for SARS-CoV-2
title Development of vaccines for SARS-CoV-2
title_full Development of vaccines for SARS-CoV-2
title_fullStr Development of vaccines for SARS-CoV-2
title_full_unstemmed Development of vaccines for SARS-CoV-2
title_short Development of vaccines for SARS-CoV-2
title_sort development of vaccines for sars-cov-2
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431966/
https://www.ncbi.nlm.nih.gov/pubmed/32850116
http://dx.doi.org/10.12688/f1000research.25998.1
work_keys_str_mv AT ngwernhann developmentofvaccinesforsarscov2
AT liuxiang developmentofvaccinesforsarscov2
AT mahalingamsuresh developmentofvaccinesforsarscov2